250 related articles for article (PubMed ID: 38367127)
1. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
[TBL] [Abstract][Full Text] [Related]
2. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
3. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
4. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
[TBL] [Abstract][Full Text] [Related]
5. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
[TBL] [Abstract][Full Text] [Related]
6. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
7. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
9. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.
Antonarelli G; Corti C; Tarantino P; Salimbeni BT; Zagami P; Marra A; Trapani D; Tolaney S; Cortes J; Curigliano G
ESMO Open; 2023 Aug; 8(4):101608. PubMed ID: 37467660
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
18. Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
Brown EL; Shmuel S; Mandleywala K; Panikar SS; Berry NK; Rao Y; Zidel A; Lewis JS; Pereira PMR
J Nucl Med; 2023 Oct; 64(10):1638-1646. PubMed ID: 37385676
[TBL] [Abstract][Full Text] [Related]
19. Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer.
Chai M; Li L; Wu H; Liu Y; Yi Z; Yu H
Crit Rev Oncol Hematol; 2024 Mar; 195():104274. PubMed ID: 38295890
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Wang M; Wang K; Zhu H
Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]